Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001339139 | SCV001532860 | uncertain significance | Renal carnitine transport defect | 2020-10-25 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC22A5 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals with SLC22A5-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces leucine with proline at codon 173 of the SLC22A5 protein (p.Leu173Pro). The leucine residue is highly conserved and there is a moderate physicochemical difference between leucine and proline. |
Natera, |
RCV002226540 | SCV002078307 | uncertain significance | Decreased circulating carnitine concentration | 2021-05-24 | no assertion criteria provided | clinical testing | |
Natera, |
RCV001339139 | SCV002107430 | uncertain significance | Renal carnitine transport defect | 2021-05-24 | no assertion criteria provided | clinical testing |